FDA and Nanotech: Baby Steps Lead to Regulatory Uncertainty

Bio-Nanotechnology: A Revolution in Food, Biomedical and Health Sciences

Volumn , Issue , 2013, Pages 720-732

  Bawa, Raj ^a,b,c  

^a Bawa Biotechnology Consulting LLC   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c American Society for Nanomedicine   (United States)

Author keywords

EPA, and nanomaterial regulation; FDA and "nanogovernance"; FDA and nanotech; FDA regulated products; Nanoproducts, as combination products; Regulatory uncertainty; Safeguarding public health; Selected FDA approved nanomedicines; US, FDA regulatory agency

Indexed keywords

EID: 84887141283     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118451915.ch41     Document Type: Chapter

References (44)

1. Kuzma, J. ; Priest, S. Nanotechnology, risk, and oversight: learning lessons from related emerging technologies. Risk Analysis 30 (11), 1688-1698 (2010).
2. Bawa, R. Special report-patents and nanomedicine.Nanomedicine 2 (3), 351-374 (2007).
3. Bawa, R. Patenting inventions in bionanotechnology: a primer for scientists and lawyers.In: D.E. Reisner (editor), Bionanotechnology: Global Prospects.CRC Press, Boca Raton, FL, 2009, pp. 309-337.
4. National Nanotechnology Initiative.Available at: http://www.nano.gov/[last visited Oct. 15, 2012 ].
5. Mandel, G. Nanotechnology governance.Alabama Law Review 59 (5), 1323-1384 (2008).
6. De Jong, W.H. ; Borm, P.J.A. Drug delivery and nanoparticles: applications and hazards.International Journal of Nanomedicine 3, 133-149 (2008).
7. Sanvicens, N. ; Marco, M.P. Multifunctional nanoparticles-properties and prospects for their use in human medicine.Trends in Biotechnology 26, 425-433 (2008).
8. Bawarski, W.E. ; Chidlowsky, E. ; Bharali, D.J. ; Mousa, S.A. Emerging nanopharmaceuticals.Nanomedicine: Nanotechnology, Biology, and Medicine 4, 273-282 (2008).
9. Davis, M.E. ; Chen, Z.G. ; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer.Nature Reviews Drug Discovery 7, 771-782 (2008).
10. Linkov, I. ; Satterstrom, F.K. ; Corey, L.M. Nanotoxicology and nanomedicine: making hard decisions.Nanomedicine: Nanotechnology, Biology, and Medicine 4, 167-171 (2008).
11. Gaspar, R. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals.Nanomedicine 2, 143-147 (2007).
12. Taylor, M.R. Regulating the products of nanotechnology: does FDA have the tools it needs? Woodrow Wilson International Center for Scholars, Project on Emerging Nanotechnologies, Washington, DC., 2006.Available at: http://www.nanotechproject.org/publications/archive/regulating_products_ nanotechnology_does/[last visited Oct. 25, 2012].
13. Bawa, R. Regulating nanomedicine-can the FDA handle it? Current Drug Delivery 8, 227-234 (2011).
14. US FDA.Nanotechnology: a report of the U.S. Food and Drug Administration Nanotechnology Task Force, 23 July 2007.Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108954 .htm [last visited Oct. 25, 2012].
15. Rados, C. Nanotechnology: the size of things to come. FDA Consumer Nov.-Dec., 40-42 (2005).
16. Bawa, R. Nanoparticle-based therapeutics in humans: a survey.Nanotechnology Law and Business 5, 135-155 (2008).
17. Bawa, R. Nanopharmaceuticals.European Journal of Nanomedicine 3 (1), 34-39 (2010).
18. Mendel, G. Nanotechnology governance.Albany Law Review 59, 1323-1329 (2008).
19. US FDA.Draft guidance for industry: considering whether an FDA regulated product involves the application of nanotechnology. Available at: http://tinyurl.com/3d2qp5n [last visited Sep. 20, 2012 ].
20. US FDA.FDA Consumer Health Information, Food and Drug Administration, June 2011, p. 1.
21. Hamburg, M.A.FDA's approach to regulation of products of nanotechnology.Science 336, 299-300 (2012).
22. EC, Directive on cosmetics; http://ec.europa.eu/consumers/sectors/cosmetics/documents/directive/. [last visited Oct. 15, 2012]
23. EC, Recommendation on the definition of nanomaterial; http://ec.europa.eu/environment/chemicals/nanotech/pdf/commission_recomm endation.pdf.[last visited Sep. 5, 2012]
24. EPA's new proposed policy for nanotechnology in pesticides; www.epa.gov/pesticides/regulating/nanotechnology.html. [last visited Sep. 5, 2012]
25. Health Canada, Policy statement on Health Canada's working definition for nanomaterial, 2011 ; www.hc-sc.gc.ca/sr-sr/pubs/nano/pol-eng.php. [last visited Sep. 5, 2012]
26. National Industrial Chemicals Notification and Assessment Scheme, Australia's new chemical requirements for notification; www.nicnas.gov.au/Current_Issues/Nanotechnology.asp.[last visited Sep. 5, 2012 ]
27. Hantman, I. ; Bawa, R. ; Monica, J.C. (2013). Regulating nanomedicine at the FDA and EPA.In: R. Bawa, G. F. Audette and I. Rubinstein (editors), Handbook of Clinical Nanomedicine-From Bench to Bedside, Pan Stanford Series in Nanomedicine (R. Bawa, Series Editor), Volume 1, Pan Stanford Publishing, Singapore, 2013 (in press).
28. Bawa, R. ; Melethil, S. ; Simmons, W.J. ; Harris, D. Nanopharmaceuticals-patenting issues and FDA regulatory challenges.American Bar Association SciTech Lawyer 5 (2), 10-15 (2008).
29. Paradise, J. ; Diliberto, G. ; Tisdale A. ; Kokkoli, E. Exploring emerging nanobiotechnology drugs and medical devices.Food and Drug Law Journal 63, 407-411 (2008).
30. Miller, J. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Science and Technology Law Review 4, 1-35 (2003).
31. Gopalaswamy, V. ; Gopalaswamy, S. Combination Products: Regulatory Challenges and Successful Product Development.CRC Press, Boca Raton, FL, 2008, pp. 7-22.
32. Foote, S.B. ; Berlin, R.J. Can Regulation be as innovative as science and technology? The FDA's regulation of combination products.Minnesota Journal of Law, Science and Technology 6, 619-644 (2005).
33. Segal, S.A. Device and biologic combination products: understanding the evolving regulation. Medical Device and Diagnostic Industry Magazine (1999). Available at: http://www.mddionline.com/[last visited Oct. 15, 2012].
34. Hantman, I.A. Nanogovernance: federal progress on regulating tiny technology.BNA Daily Environment Report 152 DEN B-1, 1-8 (2011).
35. Ramachandran, G. ; Wolf, S. ; Paradise, J. ; Kuzma, J. ; Hall, R. ; Kokkoli, E. ; Fatehi, L. Recommendations for oversight of nanobiotechnology: dynamic oversight for complex and convergent technology.Journal of Nanoparticle Research 13, 1345-1371 (2011).
36. D'Silva, J. ; Bowman, D. Nanotechnology (special edition). European Journal of Law and Technology, 2 (3) (2011).
37. Reisch, L.A. ; Scholl, G. ; Bietz ., S.'Better safe than sorry': consumer perceptions of and deliberations on nanotechnologies. International Journal of Consumer Studies 1-11 (2011).
38. Belinsky, Z. NanoManagement: synergizing regulation with common law in light of nanotechnology.Nanotechnology Law and Business 7, 165-178 (2010).
39. Bunker, K.L. ; Wolfe, J. ; Wu, L. Integrating nanotechnology into the life sciences.Journal of Pharmaceutical Sciences and Nanotechnology 5 (1), 1583-1596 (2012).
40. Bhogal, N. Regulatory and scientific barriers to the safety evaluation of medical nanotechnologies.Nanomedicine 4 (5), 495-498 (2009).
41. Nel, A. ; Xia, T. ; Mädler, L. ; Li, N. Toxic potential of materials at the nanolevel.Science 311 (5761), 622-627 (2006).
42. Reed, S.D. ; Anstrom, K.J. ; Seils, D.M. ; Califf, R.M. ; Schulman, K.A. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs.Health Affairs 27 (5), 360-370 (2008).
43. Fender, J.The FDA and nano: big problems with tiny technology.Chicago-Kent Law Review 83, 1063-1095 (2008).
44. Bawa, R. Nanotechnology patent proliferation and the crisis at the US Patent Office.Albany Law Journal of Science and Technology 17 (3), 699-735 (2007).